Vapotherm, Inc. (VAPO)
USD 2.17
(-0.46%)
USD 2.17
(-0.46%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 68.66 Million USD | 2.8% |
| 2022 | 66.8 Million USD | -41.04% |
| 2021 | 113.29 Million USD | -9.89% |
| 2020 | 125.73 Million USD | 161.38% |
| 2019 | 48.1 Million USD | 13.51% |
| 2018 | 42.37 Million USD | 19.05% |
| 2017 | 35.59 Million USD | 18.18% |
| 2016 | 30.12 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 16.88 Million USD | -11.76% |
| 2024 Q1 | 19.13 Million USD | -3.04% |
| 2023 Q4 | 19.73 Million USD | 30.11% |
| 2023 Q2 | 16.03 Million USD | -9.55% |
| 2023 Q1 | 17.73 Million USD | -4.99% |
| 2023 Q3 | 15.16 Million USD | -5.42% |
| 2023 FY | 68.66 Million USD | 2.8% |
| 2022 Q4 | 18.66 Million USD | 37.79% |
| 2022 Q1 | 21.62 Million USD | -2.8% |
| 2022 FY | 66.8 Million USD | -41.04% |
| 2022 Q2 | 12.97 Million USD | -40.01% |
| 2022 Q3 | 13.54 Million USD | 4.43% |
| 2021 FY | 113.29 Million USD | -9.89% |
| 2021 Q3 | 38.11 Million USD | 84.8% |
| 2021 Q2 | 20.62 Million USD | -36.16% |
| 2021 Q1 | 32.3 Million USD | -21.02% |
| 2021 Q4 | 22.24 Million USD | -41.64% |
| 2020 FY | 125.73 Million USD | 161.38% |
| 2020 Q4 | 40.9 Million USD | 33.86% |
| 2020 Q1 | 19.11 Million USD | 46.93% |
| 2020 Q3 | 30.55 Million USD | -13.07% |
| 2020 Q2 | 35.15 Million USD | 83.9% |
| 2019 Q1 | 12.29 Million USD | 5.25% |
| 2019 Q4 | 13.01 Million USD | 20.36% |
| 2019 Q3 | 10.8 Million USD | -9.82% |
| 2019 Q2 | 11.98 Million USD | -2.54% |
| 2019 FY | 48.1 Million USD | 13.51% |
| 2018 Q2 | 10.56 Million USD | -1.64% |
| 2018 FY | 42.37 Million USD | 19.05% |
| 2018 Q4 | 11.68 Million USD | 24.46% |
| 2018 Q1 | 10.73 Million USD | 3.19% |
| 2018 Q3 | 9.38 Million USD | -11.11% |
| 2017 Q3 | 7.87 Million USD | -3.7% |
| 2017 Q4 | 10.4 Million USD | 32.09% |
| 2017 FY | 35.59 Million USD | 18.18% |
| 2017 Q1 | 8.65 Million USD | 0.0% |
| 2017 Q2 | 8.18 Million USD | -5.47% |
| 2016 FY | 30.12 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Abbott Laboratories | 40.1 Billion USD | 99.829% |
| Allurion Technologies Inc. | 53.46 Million USD | -28.432% |
| Artivion, Inc. | 354 Million USD | 80.602% |
| Avanos Medical, Inc. | 673.3 Million USD | 89.801% |
| Butterfly Network, Inc. | 65.9 Million USD | -4.202% |
| Butterfly Network, Inc. | 65.9 Million USD | -4.202% |
| Bio-Rad Laboratories, Inc. | 2.67 Billion USD | 97.429% |
| Boston Scientific Corporation | 14.24 Billion USD | 99.518% |
| Perspective Therapeutics, Inc. | 7.1 Million USD | -866.624% |
| CONMED Corporation | 1.24 Billion USD | 94.466% |
| Edwards Lifesciences Corporation | 6 Billion USD | 98.856% |
| Paragon 28, Inc. | 216.38 Million USD | 68.266% |
| Glaukos Corporation | 314.71 Million USD | 78.18% |
| Globus Medical, Inc. | 1.56 Billion USD | 95.622% |
| Inspire Medical Systems, Inc. | 624.79 Million USD | 89.009% |
| Integer Holdings Corporation | 1.59 Billion USD | 95.699% |
| Medtronic plc | 32.36 Billion USD | 99.788% |
| Nevro Corp. | 425.17 Million USD | 83.849% |
| Owlet, Inc. | 54.01 Million USD | -27.141% |
| Penumbra, Inc. | 1.05 Billion USD | 93.513% |
| Vicarious Surgical Inc. | - USD | -Infinity% |
| Smith & Nephew plc | 5.54 Billion USD | 98.762% |
| Sonendo, Inc. | 43.86 Million USD | -56.546% |
| STERIS plc | 5.13 Billion USD | 98.664% |
| Stryker Corporation | 20.49 Billion USD | 99.665% |
| Zimmer Biomet Holdings, Inc. | 7.39 Billion USD | 99.071% |